Acute infectious diarrhea as a transient ecological collapse in the gut microbiome

Acute infectious diarrhea is more than a short-lived fluid-loss syndrome. With more than 1 billion people affected each year, it represents a global clinical burden that reaches far beyond dehydration, absenteeism, and health care use. This review reframes the illness as acute dysbiosis: a sudden, pathogen-driven disruption of the intestinal ecosystem that can be severe yet often reversible. The conceptual shift matters because it moves attention from a narrow focus on the offending organism alone to the full ecological response of the host-microbiome system.

The central argument is straightforward. Infection perturbs both the structure and function of the gut microbiota, and the recovery phase is not a simple return to baseline. Recovery unfolds in stages, with the possibility of incomplete restitution if the microbial community fails to reassemble along a healthy trajectory. In practical terms, the diarrheal episode becomes a window into individual ecological vulnerability, revealing why some patients recover quickly while others may move into prolonged instability.

One of the clearest messages is that diarrhea is not only an acute syndrome; it is also a biologic stress test.

Pathogen-driven disruption and the biology of incomplete recovery

The review organizes the microbiome response around acute injury, convalescence, and longer-term ecological rebalancing. During the acute phase, pathogens alter community composition and disturb microbial functions that normally support colonization resistance, metabolic homeostasis, and mucosal signaling. Once those functions are disrupted, the host enters a recovery period in which microbial succession may proceed smoothly, stall, or drift toward an altered steady state.

This is where the framework becomes clinically useful. A patient who appears to have “recovered” symptomatically may still carry a microbiome that has not fully restored its prior diversity or function. Persistent ecological gaps can plausibly influence future susceptibility to enteric pathogens, nutrient handling, or post-infectious symptoms, even when the diarrhea itself has resolved. The review does not claim a fixed clinical biomarker for this state; instead, it emphasizes that incomplete restitution remains a real biological risk and a major research target.

The ecology is dynamic, not binary. A pathogen can clear while the microbiome remains in flux.

Microbiota-based therapies move from broad support to targeted restoration

The review places microbiota-based intervention strategies along a spectrum from established supportive approaches to investigational precision tools. Probiotics appear within the discussion as part of the current evidence base, while newer approaches such as phage therapy sit farther from routine bedside use. The emphasis is not on ranking every intervention as equivalent, but on distinguishing what is already evidence-based from what remains exploratory.

That distinction is especially important in acute infectious diarrhea, where intervention goals differ by stage. In the early phase, the clinical priority is to manage the acute illness safely. During recovery, the therapeutic question shifts toward steering ecological restoration in a direction that favors resilient community reassembly. In theory, interventions that modulate microbial composition, function, or pathogen burden could shorten the path from dysbiosis to restoration, but the review is careful not to collapse those possibilities into proven practice.

Phage therapy represents the most striking example of this translational gap. Its appeal is biologically intuitive: bacteriophages can target specific bacteria, offering a precision approach that is conceptually attractive when a pathogen is known. Yet the review places it among emerging strategies rather than ready tools, reflecting the difference between mechanistic plausibility and established clinical utility.

Artificial intelligence and multi-omics offer a route to precision restoration

A major forward-looking theme is the use of artificial intelligence to integrate multi-omics data. In this framework, the microbiome is not treated as a static laboratory readout. It becomes one layer in a larger network that may also include metabolomic, transcriptomic, and other biologic signals. AI-driven integration could, in principle, identify recovery patterns, stratify risk, and distinguish patients likely to regain ecological stability from those trending toward incomplete restoration.

Such an approach fits the complexity of infectious diarrhea better than a one-size-fits-all model. Different pathogens can produce distinct microbiome perturbations, and host factors can shape the speed and quality of recovery. A precision framework would therefore depend on more than pathogen identification alone. It would require tools capable of translating multilevel biologic data into clinically usable insight, whether for prognosis, intervention selection, or follow-up planning.

For now, those tools remain aspirational. The review positions microbiota-derived diagnostic biomarkers as a promising research direction rather than a deployable clinical test. In other words, the field is moving toward biomarker-guided care, but the evidence base has not yet crossed the threshold needed for routine implementation.

Biomarkers, bedside care, and the gap between concept and guideline

The review repeatedly separates evidence-based recommendations from investigational ideas. That restraint is important because acute infectious diarrhea is common, fast-moving, and heterogeneous. A framework built around ecological vulnerability may help clinicians think more clearly about why some patients are at higher risk of prolonged dysbiosis, but it does not replace established clinical management. Rehydration, pathogen-specific treatment when indicated, and attention to severity remain the foundation of care.

What the framework adds is a biologic lens. It invites clinicians and researchers to view the acute episode as a diagnostic opportunity, not just a symptomatic event. If the microbiome carries information about resilience, recovery speed, and future susceptibility, then stool-based or multi-omic measures could eventually help define subgroups that benefit from different restorative strategies. For now, that vision remains under development, and the review avoids presenting it as standard practice.

The most useful clinical implication may be conceptual: acute infectious diarrhea is often reversible, but reversibility is not guaranteed at the ecological level. A patient can improve clinically while remaining microbiologically vulnerable.

What this framework changes for research and practice

This review does not function as a practice guideline. It functions as a map of where the field stands and where it could go next. The map is built around three linked ideas: acute dysbiosis during infection, staged recovery with the risk of incomplete restitution, and a future in which microbiota-based interventions are matched more precisely to individual biology. That structure helps explain why the microbiome has become central to modern diarrhea research.

The unfinished work is substantial. Better definitions of recovery are needed. Biomarkers still need validation. Microbiota-directed interventions need stronger evidence before they can move into routine care. AI-assisted multi-omics may eventually connect those pieces, but the review makes clear that precision restoration remains a goal, not a present-day standard.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Gut (BMJ).